MAPT and Alzheimer disease: A recent study of p-tau217 study comparing 10 plasma p-tau assays in prodromal AD cohorts suggested that mass-spectrometry-based measures of p-tau217 was able to identify MCI patients who will subsequently progress to AD dementia with high probability (AUC = 0.932) whereas other non-mass spectrometry-based Simoa, Lumipulse immunoassay, Meso Scale Discovery immunoassay, and Splex immunoassay yielded wide AUC range from 0.688–0.889 in predicting future progression to AD dementia (Janelidze et al., 2023).